Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
View Patent ↗The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one of lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in increasing insulin sensitivity and/or reducing insulin resistance. This composition optionally further comprises 2′-fucosyllactose (FL). This composition is particularly adapted for use in infants who were born preterm and/or who experienced IUGR, in pregnant women suffering from gestational diabetes and in children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.
1. A method for increasing insulin sensitivity and/or reducing insulin resistance in an individual suffering from insulin resistance, the method comprising administering to the individual a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and an oligosaccharide mixture, the mixture containing (i) at least one of Galβ1,4GlcNAcβ1,3Galβ1,4Glc and Galβ1,3GlcNAcβ1,3Galβ1,4Glc (ii) at least one N-acetylated oligosaccharide different from lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), (iii)at least one sialylated oligosaccharide and (iv) at least one neutral oligosaccharide,
the at least one N-acetylated oligosaccharide different from LNnT and LNT is selected from the group consisting of GalNAcα1,3Galβ1,4Glc, 4Glc and Galβ1,6GalNAcα1,3Galβ1,4Glc, the at least one sialylated oligosaccharide is selected from the group comprising NeuAcα2,3Galβ1,4Glc and NeuAcα2,6Galβ1,4Glc, and the at least one neutral oligosaccharide is selected from the group consisting of Fucα1,2Galβ1,4Glc; Galβ1,6Gal; Galβ1,6Galβ1,4Glc; Galβ1,6Galβ1,6Glc; Galβ1,3 Galβ1,3 Glc; Galβ1,3Galβ1,4Glc; Galβ1,6Galβ1,6Galβ1,4Glc; Galβ1,6Galβ1,3Galβ1,4Glc; Galβ1,3Galβ1,6Galβ1,4Glc; Galβ1,3GaIβ1,3Galβ1,4Glc; Galβ1,4Galβ1,4Glc and Galβ1,4GaIβ1,4Galβ1,4Glc.
2. The method of claim 1 , wherein the at least one neutral oligosaccharide comprises Fucα1,2Galβ1,4Glc.
3. The method of claim 1 , wherein the oligosaccharide mixture comprises:
10-60 wt % with respect to the total weight of the oligosaccharide mixture, of at least one of lacto-N-neo-tetraose (LNnT) and lacto-N-tetraose (LNT),
0.25-20 wt % with respect to the total weight of the oligosaccharide mixture, of the at least one N-acetylated oligosaccharide different from LNnT and LNT,
0.5-30 wt % with respect to the total weight of the oligosaccharide mixture, of the at least one sialylated oligosaccharide, and
20-80 wt % with respect to the total weight of the oligosaccharide mixture, of the at least one neutral oligosaccharide.
4. The method of claim 3 , wherein the at least one neutral oligosaccharide comprises 2′-fucosyllactose (FL), and the ratio between LNnT and/or LNT and the FL is from 0.1:1 to 1.5:1.
5. The method of claim 4 , wherein the ratio between the at least one of LNnT and LNT and the FL is from 0.2:1 to 1.0:1.
6. The method of claim 1 , wherein the oligosaccharide mixture is 0.5-70% of the total weight of the composition.
7. The method of claim 1 , wherein the one LC-PUFA is selected from the group consisting of arachidonic acid (ARA) and docosahexanoic acid (DHA).
8. The method according of claim 1 , wherein the at least probiotic is selected from the group consisting of Bifidobacterium lactis and Lactobacillus reuteri.
9. The method of claim 1 , wherein the at least one sialylated oligosaccharide is selected from the group consisting of 3′-sialyllactose and 6′-sialyllactose.
10. The method of claim 1 , wherein the at least one neutral oligosaccharide is selected from the group consisting of fructooligosaccharides (FOS) and galactooligosaccharides (GOS).
11. The method of claim 1 , wherein the composition is selected from the group consisting of a preterm infant formula, a human milk fortifier, a starter infant formula, a follow-on formula, a baby food formula, an infant cereal formula, a growing-up milk, a medical food product for clinical nutrition, a yogurt, a soup, a milk-based product, a frozen food, a bar, a breakfast cereal, a canned food, a pet food and a supplement.
12. The method of claim 1 , wherein the composition is selected from the group consisting of a preterm infant formula, a human milk fortifier, and a supplement.
13. The method of claim 1 , wherein the individual is selected from the group consisting of (i) an infant who was born preterm and/or who experienced intra-uterine growth restriction (IUGR, (ii) pregnant women suffering from gestational diabetes, and (iii) children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.
14. The method of claim 1 , wherein the individual is selected from the group consisting of (i) pregnant women suffering from gestational diabetes and (ii) children, adolescents, and adults suffering from insulin resistance and/or type II diabetes.
15. The method of claim 1 , wherein the oligosaccharide mixture is 1-20% of the total weight of the composition.
16. The method of claim 1 , wherein the oligosaccharide mixture comprises:
20-40 wt. % with respect to the total weight of the oligosaccharide mixture, of at least one of lacto-N-neo-tetraose (LNnT) and lacto-N-tetraose (LNT),
0.3-5 wt. % with respect to the total weight of the oligosaccharide mixture, of the at least one N-acetylated oligosaccharide different from LNnT and LNT,
0.75-10 wt. % with respect to the total weight of the oligosaccharide mixture, of the at least one sialylated oligosaccharide, and
50-90 wt. % with respect to the total weight of the oligosaccharide mixture, of the at least one neutral oligosaccharide.
17. The method of claim 1 , wherein the at least one sialylated oligosaccharide comprises 3′-sialyllactose and 6′-sialyllactose in a ratio between 5:1 and 1:2.
18. The method of claim 1 , wherein the individual is an infant or young child.
19. A method for increasing insulin sensitivity and/or reducing insulin resistance in an infant or young child who is predisposed for developing insulin resistance, the method comprising administering to the infant or young child a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and an oligosaccharide mixture, the mixture containing (i) at least one of Galβ1,4GlcNAcβ1,3Galβ1,4Glc and Galβ1,3GlcNAcβ1,3Galβ1,4Glc, (ii) at least one N-acetylated oligosaccharide different from lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), (iii) at least one sialylated oligosaccharide and (iv) at least one neutral oligosaccharide wherein,
the at least one N-acetylated oligosaccharide different from LNnT and LNT is selected from the group consisting of GalNAcα1,3Galβ1,4Glc and Galβ1,6GalNAcα1,3Galβ1,4Glc, the at least one sialylated oligosaccharide is selected from the group comprising NeuAcα2,3Galβ1,4Glc and NeuAcα2,6Galβ1,4Glc, and the at least one neutral oligosaccharide is selected from the group consisting of Fucα1,2Galβ1,4Glc; Galβ1,6Gal; Galβ1,6Galβ1,4Glc; Galβ1,6Galβ1,6Glc; Galβ1,3Galβ1,3Glc; Galβ1,3Galβ1,4Glc; Galβ1,6Galβ1,6Galβ1,4Glc; Galβ1,6Galβ1,3Galβ1,4Glc; Galβ1,3Galβ1,6Galβ1,4Glc; Galβ1,3GaIβ1,3Galβ1,4Glc; Galβ1,4Galβ1,4Glc and Galβ1,4GaIβ1,4Galβ1,4Glc.